The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
出版年份 2012 全文链接
标题
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
作者
关键词
-
出版物
BJU INTERNATIONAL
Volume 110, Issue 11b, Pages E575-E582
出版商
Wiley
发表日期
2012-06-16
DOI
10.1111/j.1464-410x.2012.11286.x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature
- (2011) Guru Sonpavde et al. EUROPEAN UROLOGY
- New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
- (2011) Himisha Beltran et al. EUROPEAN UROLOGY
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2011) Nicolas Mottet et al. EUROPEAN UROLOGY
- Current Vaccination Strategies for Prostate Cancer
- (2011) Steven Joniau et al. EUROPEAN UROLOGY
- Expanding Treatment Options for Metastatic Prostate Cancer
- (2011) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
- (2011) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Characteristics and Outcomes of Patients With Advanced Gastric Cancer Who Declined to Participate in a Randomized Clinical Chemotherapy Trial
- (2011) Chiharu Tanai et al. Journal of Oncology Practice
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials
- (2009) C Tanai et al. BRITISH JOURNAL OF CANCER
- Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
- (2009) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
- (2009) Jianqing Lin et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Influence of Clinical Communication on Patients' Decision Making on Participation in Clinical Trials
- (2008) Terrance L. Albrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now